scholarly journals Idelalisib for optimized CD19‐specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients

2019 ◽  
Vol 145 (5) ◽  
pp. 1312-1324 ◽  
Author(s):  
Sophia Stock ◽  
Rudolf Übelhart ◽  
Maria‐Luisa Schubert ◽  
Fuli Fan ◽  
Bailin He ◽  
...  
Keyword(s):  
T Cells ◽  
Chronic Lymphocytic Leukemia ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Lymphocytic Leukemia

scholarly journals In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor

Blood ◽  
2011 ◽  
Vol 117 (18) ◽  
pp. 4736-4745 ◽  
Author(s):  
Greta Maria Paola Giordano Attianese ◽  
Virna Marin ◽  
Valentina Hoyos ◽  
Barbara Savoldo ◽  
Irene Pizzitola ◽  
...  
Keyword(s):  
T Cells ◽  
Chronic Lymphocytic Leukemia ◽  
B Lymphocytes ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Lymphocytic Leukemia ◽  
Leukemic Cells ◽  
Car T Cells ◽  
Car T

Abstract Chronic lymphocytic leukemia (CLL) is characterized by an accumulation of mature CD19+CD5+CD20dim B lymphocytes that typically express the B-cell activation marker CD23. In the present study, we cloned and expressed in T lymphocytes a novel chimeric antigen receptor (CAR) targeting the CD23 antigen (CD23.CAR). CD23.CAR+ T cells showed specific cytotoxic activity against CD23+ tumor cell lines (average lysis 42%) and primary CD23+ CLL cells (average lysis 58%). This effect was obtained without significant toxicity against normal B lymphocytes, in contrast to CARs targeting CD19 or CD20 antigens, which are also expressed physiologically by normal B lymphocytes. Moreover, CLL-derived CD23.CAR+ T cells released inflammatory cytokines (1445-fold more TNF-β, 20-fold more TNF-α, and 4-fold more IFN-γ). IL-2 was also produced (average release 2681 pg/mL) and sustained the antigen-dependent proliferation of CD23.CAR+ T cells. Redirected T cells were also effective in vivo in a CLL Rag2−/−γc−/− xenograft mouse model. Compared with mice treated with control T cells, the infusion of CD23.CAR+ T cells resulted in a significant delay in the growth of the MEC-1 CLL cell line. These data suggest that CD23.CAR+ T cells represent a selective immunotherapy for the elimination of CD23+ leukemic cells in patients with CLL.

SP-024 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS FOR RELAPSED, REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

2014 ◽  
Vol 38 ◽  
pp. S12
Author(s):  
J. Joseph Melenhorst ◽  
David L. Porter ◽  
Simon F. Lacey ◽  
Alison W. Loren ◽  
Christina Jemison ◽  
...  
Keyword(s):  
T Cells ◽  
Chronic Lymphocytic Leukemia ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Lymphocytic Leukemia

scholarly journals Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

2015 ◽  
Vol 7 (303) ◽  
pp. 303ra139-303ra139 ◽  
Author(s):  
David L. Porter ◽  
Wei-Ting Hwang ◽  
Noelle V. Frey ◽  
Simon F. Lacey ◽  
Pamela A. Shaw ◽  
...  
Keyword(s):  
T Cells ◽  
Chronic Lymphocytic Leukemia ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Lymphocytic Leukemia

scholarly journals CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile

2018 ◽  
Vol 41 (2) ◽  
pp. 73-83 ◽  
Author(s):  
Isabelle Magalhaes ◽  
Ingrid Kalland ◽  
James N. Kochenderfer ◽  
Anders Österborg ◽  
Michael Uhlin ◽  
...  
Keyword(s):  
T Cells ◽  
Chronic Lymphocytic Leukemia ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Lymphocytic Leukemia ◽  
Ifn Γ

scholarly journals Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia

HemaSphere ◽  
2019 ◽  
pp. 1
Author(s):  
Julio Delgado ◽  
Miguel Caballero-Baños ◽  
Valentín Ortiz-Maldonado ◽  
Maria Castellà ◽  
Laura Magnano ◽  
...  
Keyword(s):  
T Cells ◽  
Chronic Lymphocytic Leukemia ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Lymphocytic Leukemia
Sign in / Sign up

Export Citation Format

Share Document